These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2057989)

  • 1. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
    Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
    Lafolie P; Hayder S; Björk O; Peterson C
    Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
    Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
    Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability.
    Lönnerholm G; Kreuger A; Lindström B; Myrdal U
    Pediatr Hematol Oncol; 1989; 6(2):105-12. PubMed ID: 2702064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
    Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
    Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
    Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
    Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
    J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
    Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
    Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.
    Lafolie P; Björk O; Hayder S; Ahström L; Peterson C
    Med Oncol Tumor Pharmacother; 1989; 6(4):259-65. PubMed ID: 2615529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
    Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
    Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia.
    Jacqz-Aigrain E; Nafa S; Médard Y; Bessa E; Lescoeur B; Vilmer E
    Eur J Clin Pharmacol; 1997; 53(1):71-4. PubMed ID: 9349933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
    Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
    N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
    Ogungbenro K; Aarons L;
    J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
    Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
    Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
    Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
    Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia--interindividual and intraindividual variations].
    Hijiya N; Kato Y; Matsushita T; Yokoyama T
    Rinsho Ketsueki; 1989 Nov; 30(11):1931-6. PubMed ID: 2607612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
    Hayder S; Björk O; Lafolie P
    Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
    Hale JP; Lilleyman JS
    Arch Dis Child; 1991 Apr; 66(4):462-6. PubMed ID: 2031601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.